Timothy R. Wilson

ScholarGPS® ID: 72644420741125

Affiliation

Genentech, Inc., South San Francisco, United States

Affiliation History

Field

Medicine

Discipline

Oncology

Top Specialties

Metrics Summary

Publication Count

Predicted Citations

4,645

Predicted h-index

Ranking

Publications and Citation History

Publications based on Top Specialties

Types of Publication

Publications
Books
Patents
NIH/NSF

Add Delete
Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial. (journal article) Dziadziuszko, Rafal \| Barlesi, Fabrice \| Kim, Jeong Eun \| Gadgeel, Shirish M. \| Krzakowski, Maciej \| Jeong, Jae Ho \| Daniele, Gennaro \| Chen, David \| Hu, Youyou \| Wilson, Timothy R. \| ... \| Thomas, David Morgan Journal of Clinical Oncology, volume 42, issue 17_suppl, pages LBA2509-LBA2509 (2024). 10.1200/JCO.2024.42.17_suppl.LBA2509 Cite \| Source
Ipatasertib in patients with AKT1/2/3 mutation-positive ( AKT mut) tumors: TAPISTRY study. (journal article) Thomas, David Morgan \| Daniele, Gennaro \| Kim, Jeong Eun \| Gadgeel, Shirish M. \| Ahn, Eugene R. \| Paz-Ares, Luis G. \| Prenen, Hans \| Chen, David \| Fang, Junhan \| Wilson, Timothy R. \| ... \| Barlesi, Fabrice Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 3092-3092 (2024). 10.1200/JCO.2024.42.16_suppl.3092 Cite \| Source
ER +, HER2 − advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes (journal article) Chen, Jessica W. \| Jacot, William \| Cortés, Javier \| Krop, Ian E. \| Dent, Susan \| Harbeck, Nadia \| De Laurentiis, Michelino \| Diéras, Véronique \| Im, Young‐Hyuck \| Stout, Thomas J. \| ... \| Wilson, Timothy R. Molecular Oncology, volume 17, issue 10, pages 2000-2016 (2023). 10.1002/1878-0261.13416 Cite \| Source
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers (journal article) Hutchinson, Katherine E. \| Chen, Jessica W. \| Savage, Heidi M. \| Stout, Thomas J. \| Schimmoller, Frauke \| Cortés, Javier \| Dent, Susan \| Harbeck, Nadia \| Jacot, William \| Krop, Ian \| ... \| Wilson, Timothy R. Genome Medicine, volume 15, issue 1 (2023). 10.1186/s13073-023-01181-8 Cited by (8) \| Cite \| Source
Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations (journal article) Sivakumar, Smruthy \| Jin, Dexter X. \| Rathod, Ruchita \| Ross, Jeffrey \| Cantley, Lewis C. \| Scaltriti, Maurizio \| Chen, Jessica W. \| Hutchinson, Katherine E. \| Wilson, Timothy R. \| Sokol, Ethan S. \| Vasan, Neil Clinical Cancer Research, volume 29, issue 6, pages 1125-1136 (2023). 10.1158/1078-0432.CCR-22-2270 Cited by (8) \| Cite \| Source
MET gene amplification is a mechanism of resistance to entrectinib in ROS1 + NSCLC (journal article) Tyler, Logan C. \| Le, Anh T. \| Chen, Nan \| Nijmeh, Hala \| Bao, Liming \| Wilson, Timothy R. \| Chen, David \| Simmons, Brian \| Turner, Kristen M. \| Perusse, Dean \| ... \| Doebele, Robert C. Thoracic Cancer, volume 13, issue 21, pages 3032-3041 (2022). 10.1111/1759-7714.14656 Cited by (9) \| Cite \| Source
Growth‐rate model predicts in vivo tumor response from in vitro data (journal article) Diegmiller, Rocky \| Salphati, Laurent \| Alicke, Bruno \| Wilson, Timothy R. \| Stout, Thomas J. \| Hafner, Marc CPT: Pharmacometrics & Systems Pharmacology, volume 11, issue 9, pages 1183-1193 (2022). 10.1002/psp4.12836 Cited by (5) \| Cite \| Source
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results (journal article) Lindeman, Geoffrey J. \| Fernando, Tharu M. \| Bowen, Rebecca \| Jerzak, Katarzyna J. \| Song, Xinni \| Decker, Thomas \| Boyle, Frances \| McCune, Steve \| Armstrong, Anne \| Shannon, Catherine \| ... \| Bardia, Aditya Clinical Cancer Research, volume 28, issue 15, pages 3256-3267 (2022). 10.1158/1078-0432.CCR-21-3811 Cited by (38) \| Cite \| Source
Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib (journal article) Dziadziuszko, Rafal \| Hung, Tiffany \| Wang, Kun \| Choeurng, Voleak \| Drilon, Alexander \| Doebele, Robert C. \| Barlesi, Fabrice \| Wu, Charlie \| Dennis, Lucas \| Skoletsky, Joel \| ... \| Wilson, Timothy R. Molecular Oncology, volume 16, issue 10, pages 2000-2014 (2022). 10.1002/1878-0261.13214 Cited by (10) \| Cite \| Source
NTRK gene fusions are detected in both secretory and non‐secretory breast cancers (journal article) Maund, Sophia L. \| Sokol, Ethan S. \| Ang Houle, Armande \| Ross, Jeffrey S. \| Wilson, Timothy R. Pathology International, volume 72, issue 3, pages 187-192 (2022). 10.1111/pin.13204 Cited by (7) \| Cite \| Source
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population (journal article) Westphalen, C. B. \| Krebs, M. G. \| Le Tourneau, C. \| Sokol, E. S. \| Maund, S. L. \| Wilson, T. R. \| Jin, D. X. \| Newberg, J. Y. \| Fabrizio, D. \| Veronese, L. \| ... \| de Braud, F. npj Precision Oncology, volume 5, issue 1 (2021). 10.1038/s41698-021-00206-y Cited by (100) \| Cite \| Source
Tumor-agnostic precision immuno-oncology and somatic targeting rationale for you (TAPISTRY): A novel platform umbrella trial. (journal article) Drilon, Alexander E. \| Liu, Haiying \| Wu, Felice \| Chen, David \| Wilson, Timothy Richard \| Simmons, Brian P. \| Barlesi, Fabrice Journal of Clinical Oncology, volume 39, issue 15_suppl, pages TPS3154-TPS3154 (2021). 10.1200/JCO.2021.39.15_suppl.TPS3154 Cited by (8) \| Cite \| Source
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer (journal article) Dziadziuszko, Rafal \| Krebs, Matthew G. \| De Braud, Filippo \| Siena, Salvatore \| Drilon, Alexander \| Doebele, Robert C. \| Patel, Manish R. \| Cho, Byoung Chul \| Liu, Stephen V. \| Ahn, Myung-Ju \| ... \| Barlesi, Fabrice Journal of Clinical Oncology, volume 39, issue 11, pages 1253-1263 (2021). 10.1200/JCO.20.03025 Cited by (79) \| Cite \| Source
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial (journal article) Dent, S. \| Cortés, J. \| Im, Y.-H. \| Diéras, V. \| Harbeck, N. \| Krop, I.E. \| Wilson, T.R. \| Cui, N. \| Schimmoller, F. \| Hsu, J.Y. \| ... \| Jacot, W. Annals of Oncology, volume 32, issue 2, pages 197-207 (2021). 10.1016/j.annonc.2020.10.596 Cited by (96) \| Cite \| Source
1193P Clinical validity of FoundationOne liquid CDx (F1L CDx) assay as an aid in selecting patients for treatment with entrectinib (journal article) Dziadziuszko, R. \| André, F. \| Yip, W.-K. \| Wu, X. \| Skoletsky, J. \| Woodhouse, R. \| Hung, T. \| Wilson, T.R. \| Riehl, T. \| Dennis, L. \| Li, M. Annals of Oncology, volume 31 (2020). 10.1016/j.annonc.2020.08.087 Cited by (3) \| Cite \| Source
3O Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with fulvestrant in oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, PIK3 (journal article) Jacot, W. \| Savage, H.M. \| Dent, S. \| Cortés, J. \| Im, Y-H. \| Dieras, V.C. \| Harbeck, N. \| Krop, I.E. \| Chen, J. \| Sokol, E. \| ... \| Wilson, T.R. Annals of Oncology, volume 31 (2020). 10.1016/j.annonc.2020.03.139 Cited by (1) \| Cite \| Source
First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma (journal article) Wen, Patrick Y. \| Cloughesy, Timothy F. \| Olivero, Alan G. \| Morrissey, Kari M. \| Wilson, Timothy R. \| Lu, Xuyang \| Mueller, Lars U. \| Coimbra, Alexandre F. \| Ellingson, Benjamin M. \| Gerstner, Elizabeth \| ... \| Rodon, Jordi Clinical Cancer Research, volume 26, issue 8, pages 1820-1828 (2020). 10.1158/1078-0432.CCR-19-2808 Cited by (53) \| Cite \| Source
Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models (journal article) Moore, Heather M. \| Savage, Heidi M. \| O'Brien, Carol \| Zhou, Wei \| Sokol, Ethan S. \| Goldberg, Michael E. \| Metcalfe, Ciara \| Friedman, Lori S. \| Lackner, Mark R. \| Wilson, Timothy R. Molecular Cancer Therapeutics, volume 19, issue 1, pages 292-303 (2020). 10.1158/1535-7163.MCT-19-0284 Cited by (9) \| Cite \| Source
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer (journal article) Abramson, Vandana G. \| Oliveira, Mafalda \| Cervantes, Andrés \| Wildiers, Hans \| Patel, Manish R. \| Bauer, Todd M. \| Bedard, Philippe L. \| Becerra, Carlos \| Richey, Stephen \| Wei, Michael C. \| ... \| Krop, Ian E. Breast Cancer Research and Treatment, volume 178, issue 1, pages 121-133 (2019). 10.1007/s10549-019-05360-3 Cited by (4) \| Cite \| Source
Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2 (journal article) Doebele, R.C. \| Dziadziuszko, R. \| Drilon, A. \| Shaw, A. \| Wolf, J. \| Farago, A.F. \| Dennis, L. \| Riehl, T. \| Simmons, B. \| Wu, C. \| ... \| Wilson, T.R. Annals of Oncology, volume 30 (2019). 10.1093/annonc/mdz394.017 Cited by (17) \| Cite \| Source